LeadAction|Breast Cancer du Sein Competition
Frequently asked questions

PROJECT ELIGIBILITY

Can I consider the expertise of a research laboratory as an expertise equivalent to a specialized drug discovery core facility (platform)?
A specialized core facility with emphasis on drug development, facilitates and accelerates development of small molecules or biotherapies using several different approaches from the molecular biology to the preclinical and sometimes clinical expertise. Expertise acquired within a laboratory cannot replace the global services proposed by a specialized drug discovery core facility.

Is it an obligation to use services from the Institute for Research in Immunology and Cancer (IRIC) core facilities if we want to apply at the LeadAction|Breast Cancer du Sein Competition?
Applicants who need to use drug discovery core facilities are invited to refer to those of the Institute for Research in Immunology and Cancer (IRIC) - Université de Montréal (UdeM). However, applicants remain free to consider specialized drug discovery core facilities of his/her choice.

Which stages are eligible and fundable in the LeadAction|Breast Cancer du Sein Competition for a biotherapy?
As the development of small molecules, eligible and fundable translational research activities used to develop biotherapy projects, are the same. For example, *in vitro* and *in vivo* pharmacological characterization, toxicity evaluation, metabolism, identification of pharmaceutical profile, etc…

Are diagnostic projects or platforms eligible at the LeadAction|Breast Cancer du Sein Competition?
Eligible projects to the LeadAction|Breast Cancer du Sein Competition are related to the development of small molecules or biotherapies (antibodies, oncolytic viruses, cell products such as stem cells or T cells, synthetic peptides, ribonucleic acid (RNA)-based approaches, etc.). This list is non-exhaustive.

If I use a service from a specialized drug discovery core facilities localised in my Institution, do I have to include a quote in my complete application?
For all services from drug discovery core facilities, a quote must be included in the complete application.

APPLICANTS' ELIGIBILITY

Is it mandatory to have a collaboration with a Principal Investigator from IRIC to submit a project at the LeadAction|Breast Cancer du Sein Competition?
It is not mandatory to add a Principal Investigator from IRIC in the research team to submit a project at the LeadAction|Breast Cancer du Sein Competition,

Can I apply <u>ALONE</u> at the LeadAction|Breast Cancer du Sein Competition without Collaborators affiliated to a Quebec province?
The grantee (Principal Investigator) must be a University Investigator or a Clinical University Investigator from an institution, centre, research institute or department affiliated to a Quebec-based university OR to a Canada-based university.

I am a Principal Investigator and my Institution is located outside of the Quebec province, can I apply alone at the LeadAction|Breast Cancer du Sein Competition?
If the Principal Investigator is affiliated to an Institution based in a Canadian province OUTSIDE Quebec, the Principal Investigator must then integrate a collaborator affiliated to a Quebec-based Institution.

REQUIRED DOCUMENTS

What kind of information does the letter of support from the administrators of the Institution or university department in which the Principal Investigator's research will be carried out, should indicate?
The letter of support must mention that the administrators of the Institution or university department in which the Principal Investigator's research will be carried out is committed to support the Principal investigator through administrative support, access to facilities…

AMOUNT OF THE GRANT

As a grantee, can I spend more than 50% of the allocated funds outside the Quebec province?
For each funded project, 50% of the funds are to be spent in Quebec towards drug discovery activities.

Can I manage in parallel hit to lead transition activities and lead optimization activities?
Hit to lead transition activities and lead optimization activities can be managed in parallel. A maximum amount of $250,000 per year can be asked.

Can I manage in parallel lead optimization activities and preclinical studies?
Lead optimization activities and preclinical studies can be managed in parallel. A maximum amount of $500,000 per year can be asked.

CONFIDENTIALITY

Do I have to include confidential information in the notice of intent/complete application?
It remains the responsibility of the Principal Investigator to present necessary and sufficient information allowing the review Committee to assess the project. All information from the notice of intent/complete application transmitted to the Promotors of the LeadAction|Breast Cancer du Sein Competition and to the review Committee, will be processed with complete confidentiality, in compliance with the policies of IRICoR and the Quebec Breast Cancer Foundation.